Related Experiment Video
Updated: Aug 6, 2026
On-Chip Endothelial Inflammatory Phenotyping
Published on: July 21, 2012
Author's Reply to "Microvascular angina beyond risk markers: the need for endotype-specific validation"
Satoru Suzuki1,2, Kenichi Tsujita3
1Department of Cardiovascular Medicine, Center for Metabolic Regulation of Healthy Aging, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto City, 860-8556, Japan.
None:
We thank Birgün et al. for their thoughtful comments regarding our recent study on microvascular angina (MVA). In this reply, we address concerns regarding the selection of control group, medication-related confounding, and the heterogeneity of MVA endotypes. We acknowledge the limitations inherent to our retrospective case-control design while emphasizing that the observed associations between mildly elevated HbA1c, low high-density lipoprotein cholesterol, low hemoglobin levels, and MVA remained significant. We hope that these findings will stimulate further prospective investigations into the pathophysiology and clinical characteristics of MVA.
